Shotgun genetic engineering lets mammalian cells test millions of designs at once

Metabolic engineering has long delivered spectacular results in microbes, yet mammalian cells have remained stubbornly resistant to the same design logic. A new study published in Nature Biotechnology reports a strategy called shotgun genetic engineering, or SGE, that aims to change that. Rather than testing one genetic design at a time, the approach screens millions of combinatorial solutions within a single experiment, using selection schemes that allow only the effective designs to reveal themselves. The work, described in an analysis piece by Trolle and colleagues alongside the underlying research article, positions multiplexed exploration as the missing toolset for programming complex functions into mammalian genomes.

The core problem the authors confront is combinatorial explosion. Engineering a complex phenotype in a cell typically requires coordinating many genetic changes at once: overexpressing some genes, knocking others down, tuning promoters, and redirecting flux through metabolic networks that span multiple subcellular compartments. Each additional variable multiplies the number of possible designs exponentially. A pathway requiring twenty genetic parts, each with even a handful of candidate variants, generates more combinations than any laboratory could feasibly build and characterize one by one. In bacteria and yeast, researchers have partially sidestepped this wall with pooled libraries and selection, but mammalian cells, with their larger genomes, slower growth, and more elaborate regulation, have lagged behind.

Shotgun genetic engineering borrows the logic of shotgun sequencing and applies it to design. Instead of assembling a complete, specified genetic program and hoping it works, the method introduces a massively diverse pool of genetic variants into a cell population simultaneously. Each cell receives a different random combination of the parts being tested. A carefully chosen selection strategy then acts as the filter: only cells whose particular combination of edits produces the desired biological function survive, proliferate, or emit a measurable signal. Deciphering which combinations the survivors carry effectively reverse-engineers working designs out of the vast design space, without the researchers ever having to guess them in advance.

The authors frame this as a way of making complex phenotypes tractable engineering targets. In their Research Briefing, they note that engineering complex functions into mammalian cells holds profound potential but remains largely intractable, and that SGE’s selection strategies reveal effective designs, facilitating rapid engineering of complex biological functions. The emphasis on selection is crucial. Without a way to distinguish cells that have acquired the desired property from the overwhelming majority that have not, a pool of millions of variants is simply noise. With one, the experiment becomes a search algorithm executed in biological hardware, where evolution-like pressure does the computational heavy lifting.

The study builds on a growing body of work showing that mammalian metabolism can be rewired when the right tools exist. In earlier research, some of the same authors resurrected an essential amino acid biosynthesis pathway in Chinese hamster ovary cells, the workhorse of the biopharmaceutical industry, demonstrating that CHO cells could be engineered to produce valine, an amino acid that mammalian cells normally must import from their environment. That feat, published in eLife in 2022, required solving a multi-gene design problem in a mammalian background and hinted at how valuable a high-throughput search method would be for tackling even more ambitious metabolic programs.

The broader field has been converging on the same conclusion from different directions. A landmark demonstration of metabolic engineering in yeast, published in Nature in 2020, saw researchers reconstruct the biosynthesis of medicinal tropane alkaloids by overexpressing twenty-six genes distributed across six subcellular locations. That achievement showed how intricate multi-compartment engineering could be, but it also underscored the cost: such projects traditionally demand years of iterative, hypothesis-driven tuning. Reviews of cellular metabolism engineering have argued that progress depends on design-build-test-learn cycles, and the bottleneck in mammalian systems has consistently been the scale at which designs can be built and tested.

SGE attacks that bottleneck directly by collapsing the build and test phases into a single pooled experiment. The companion research article, published in Nature Biotechnology by Trolle and colleagues under the title describing highly multiplexed mammalian metabolic engineering with a shotgun approach, provides the experimental demonstration of the concept. Related efforts are pushing in parallel directions: a 2026 Nature paper described a method called CLASSIC for ultra-high-throughput mapping of genetic design space, aimed at optimizing gene circuit designs. Together, these developments suggest that the 2020s are the decade in which mammalian synthetic biology acquires the search-based toolkit that microbial engineering has enjoyed for years.

The implications for biomanufacturing are substantial. CHO cells produce the majority of approved therapeutic proteins, and their metabolism directly determines yield, product quality, and culture robustness. If SGE can routinely identify genetic configurations that improve these traits, it could compress optimization campaigns that once took years into far shorter timelines. Beyond manufacturing, the same logic applies to cell therapies, where engineering immune cells to program complex biological functions, as envisioned in influential reviews of the cell engineering era, requires navigating combinatorial design spaces of receptors, regulators, and metabolic circuits that no rational approach can fully explore.

There are, of course, constraints inherent to the approach that the authors themselves acknowledge through their framing. SGE depends on the existence of a workable selection strategy, which means the desired phenotype must be coupled to survival, growth, or a sortable signal. Phenotypes that are difficult to select for, such as subtle changes in product glycosylation or complex behavioral outputs, will require creative proxy selections or multi-step screening schemes. The method also yields designs that work, but the interpretive step of understanding why they work remains a separate challenge, one that increasingly falls to sequencing, computational modeling, and the growing repertoire of high-throughput genetic mapping techniques.

Even with those caveats, the arrival of a genuinely multiplexed engineering strategy for mammalian cells marks a shift in what is considered feasible. The field has watched metabolic engineering transform yeast into producers of plant-derived medicines and bacteria into chemical factories, while mammalian cell engineering advanced more slowly, one careful modification at a time. By screening millions of combinatorial solutions in a single experiment and letting selection reveal the winners, shotgun genetic engineering promises to bring the exploratory power of pooled library approaches to the most medically and industrially relevant cell types in biology. If the approach generalizes as its proponents hope, the design of mammalian cells with complex, custom-built functions may soon look less like artisanal craft and more like an engineering discipline with search, iteration, and scale at its core.

Subject of Research: High-throughput multiplexed metabolic engineering of mammalian cells using shotgun genetic engineering

Article Title: High-throughput metabolic engineering in mammalian cells

Article References: High-throughput metabolic engineering in mammalian cells. (2026). Nature Biotechnology. https://doi.org/10.1038/s41587-026-03317-8

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03317-8

Keywords: metabolic engineering, mammalian cells, shotgun genetic engineering, CHO cells, combinatorial design, genetic engineering, synthetic biology, Nature Biotechnology, selection strategies, biomanufacturing, cell therapy, high-throughput screening